ELI LILLY & Co
At today's price, ELI LILLY & Co (LLY) is priced for today's economics sustained for ~5.3 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Eli Lilly has become the dominant force in the GLP-1 drug class, with Mounjaro and Zepbound driving Q1 2026 revenue up 56% to $19.8 billion, and the recent FDA approval of an oral version, orforglipron, opening a far larger addressable market than injectables alone [Source: Q1 FY2026 earnings release]. • The defining risk is concentration married to price: the 10-K states Lilly derives ⟦"a significant percentage of our total revenue from relatively few products"⟧, and the stock trades at rough
Is LLY overvalued? See what's priced in →
4,266 institutional managers reported holding LLY in 13F filings for the quarter ended 2026-03-31. Together they hold about 85% of the company; the top 10 hold 48%. 161 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 9.7M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
LLY has cut its share count 1.4% over the past five years, spending $11.96B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 11 years straight; the current rate is $6.23 a share annually. Cash returned over the past three years: $13.65B in dividends and $8.96B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at LLY over the trailing three years: 2025: 9 buys totaling $4.54M. 28 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
LLY's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | +15.9% | +15.0% |
| 2023-11-03 | +2.4% | +8.9% |
| 2024-02-22 | +0.6% | -5.8% |
| 2024-05-01 | +5.4% | +15.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
LLY's latest 8-K filings: 2026-05-20 (items 8.01, 9.01); 2026-05-07 (items 5.07); 2026-04-30 (items 2.02, 9.01); 2026-02-04 (items 2.02, 9.01); 2025-11-21 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.